Media Relations

Catch up on all H3 news and developments regarding research, ongoing trials and personnel.

In the News

Fierce Biotech

Chutes & Ladders

Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Read More

BioSpace Movers & Shakers

H3, a subsidiary of Eisai Co., named Antonio Gualberto as its new CMO. Gualberto will oversee global clinical research &… Read More

Fixes in Financing

High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More
European Business Review

Personal Medicine

Biomarker research is fundamental to the delivery of targeted therapeutics. An industry shift towards a more collaborative approach to patient-derived… Read More


H3 Biomedicine was founded in 2011 as a research and development engine focused on advancing drugs from bench to bedside.

For all media interested in speaking to members of H3 Biomedicine’s team, or receiving further information about the company or pipeline, please contact us.

Want to learn more about H3 from our team?